Alprolix
eftrenonacog alfa
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Alprolix. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Alprolix.
For practical information about using Alprolix, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Alprolix : EPAR - Summary for the public (PDF/75.56 KB)
First published: 25/05/2016
Last updated: 25/05/2016
EMA/171272/2016 -
-
List item
Alprolix : EPAR - Risk-management-plan summary (PDF/105.11 KB)
First published: 10/04/2019
Last updated: 04/11/2020
Authorisation details
Product details | |
---|---|
Name |
Alprolix
|
Agency product number |
EMEA/H/C/004142
|
Active substance |
eftrenonacog alfa
|
International non-proprietary name (INN) or common name |
eftrenonacog alfa
|
Therapeutic area (MeSH) |
Hemophilia B
|
Anatomical therapeutic chemical (ATC) code |
B02BD04
|
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Swedish Orphan Biovitrum AB (publ)
|
Revision |
8
|
Date of issue of marketing authorisation valid throughout the European Union |
12/05/2016
|
Contact address |
SE-112 76 Stockholm |
Product information
09/09/2021 Alprolix - EMEA/H/C/004142 - II/0036/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Vitamin K and other hemostatics
-
Blood coagulation factors
Therapeutic indication
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).